Innoviva: Pay

Innoviva paid its 2 named executives $6.5M in total in FY2025 (Dec). CEO Pavel Raifeld was paid $5.4M of that.

Pay$100 in the stock at the end of FY21 → $116
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Pavel RaifeldChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Marianne ZhenChief Accounting Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Stephen BassoChief Financial Officer and President of IST
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 3 peers with pay on file was $8.5M. The CEO of Innoviva was paid $5.4M, 36% below the median.

  1. 1Cogent Biosciences
  2. 2Travere Therapeutics
  3. 3Innoviva
  4. 4Agios Pharmaceuticals
  5. 5Amarin Corporation plcNot disclosed
  6. 6Arvinas, Inc.Not disclosed
  7. 7Catalyst Pharmaceuticals, Inc.Not disclosed
  8. 8Coherus BioSciences, Inc.Not disclosed
  9. 9DRI Healthcare TrustNot disclosed
  10. 10Ligand PharmaceuticalsNot disclosed
  11. 11MacroGenics, Inc.Not disclosed
  12. 12Morphic Holding, Inc.Not disclosed
  13. 13Savara Inc.Not disclosed
  14. 14SpringWorks Therapeutics, Inc.Not disclosed
  15. 15Theravance Biopharma, Inc.Not disclosed
  16. 16Verona Pharma plcNot disclosed
  17. 17Xencor, Inc.Not disclosed
  18. 18Xeris Biopharma HoldingsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.